KPV · GHK-Cu · BPC-157 · TB-500 blend

KLOW in Canada

Also known as KLOW blend · KPV + GHK-Cu + BPC-157 + TB-500 · KLOW peptide · Anti-inflammatory repair blend

KLOW is a four-peptide blend that adds the anti-inflammatory tripeptide KPV to the GHK-Cu, BPC-157 and TB-500 base used in GLOW, in a single lyophilised vial. The rationale is to layer inflammatory-pathway suppression under the matrix, angiogenic and cell-migration mechanisms of the other three. No published study has tested the four together; the evidence is the separate literature on each component, all of it preclinical. Canada Peptides carries research-grade KLOW as a single vial, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Multi-peptide blend (α-MSH tripeptide + copper tripeptide + gastric pentadecapeptide + thymosin-β4 fragment)
Structure: KPV (3 aa) + GHK-Cu (3 aa, copper complex) + BPC-157 (15 aa) + TB-500 (Tβ4 fragment) · per-component amounts on the lot COA
Half-life: Minutes for each component in plasma; tissue effects reported to outlast circulating levels
Route in research: Subcutaneous in the research literature for all four; KPV also oral and topical in models
Cadence in research: Once daily in most animal protocols for each component; no protocol exists for the blend
Storage: Lyophilised: refrigerated, dark. Reconstituted: refrigerated, used within weeks; solution is blue from the copper complex
Status in Canada

KLOW FAQ

Is KLOW for sale in Canada?

Yes. Research-grade KLOW — a single vial combining KPV, GHK-Cu, BPC-157 and TB-500 — is available in Canada from Canada Peptides, priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption.

What is in the KLOW peptide blend?

Four peptides in one lyophilised vial: KPV, the anti-inflammatory C-terminal tripeptide of α-MSH; GHK-Cu, the copper-binding tripeptide; BPC-157, the gastric pentadecapeptide; and TB-500, the actin-binding fragment of thymosin β4. The per-component amounts are stated on each lot's certificate of analysis.

What is the difference between KLOW and GLOW?

KPV. GLOW contains GHK-Cu, BPC-157 and TB-500; KLOW adds KPV to that base, bringing an anti-inflammatory α-MSH pathway into the blend. Both are supplied as single vials, so read the composition before assuming equivalence with the standalone products.

What does the research on KLOW show?

Nothing directly — no published study has tested the four peptides together. The rationale rests on separate literatures: KPV's rodent colitis and skin-inflammation models, GHK-Cu's wound-healing and gene-expression work, BPC-157's rodent repair literature, and thymosin β4's preclinical and early clinical repair studies. The joint effect is untested.

What does KPV add to the blend?

An anti-inflammatory mechanism. KPV is taken up by cells through the PepT1 transporter and reduces NF-κB activation and the production of inflammatory cytokines such as TNF-α and IL-6 in rodent and cell models. It retains α-MSH's anti-inflammatory activity without the pigmentary effects, because it does not engage melanocortin receptors the way the full hormone does.

How does a blend change the reconstitution math?

The water volume sets the total concentration, and each component's share of the per-unit figure follows from the amounts on the certificate of analysis. The four amounts are in a fixed ratio; the dosage calculator's blend mode has a KLOW preset that returns a per-unit figure for each.

What side effects does the research report?

Each component is described as well tolerated in its animal literature, and none has controlled human injectable safety data; KPV has no human study by any route. Theoretical concerns include tumour angiogenesis (BPC-157, thymosin β4), copper load in copper-handling disorders (GHK-Cu) and blunted inflammatory responses (KPV). Injection-site reactions are the most common report in applied use.

Is KLOW legal in Canada?

No component is a controlled substance, but none has Health Canada approval as an injectable and the blend has no DIN. It may be sold for laboratory research, which is how it is sold here. The FDA declined to permit BPC-157, GHK-Cu and KPV in compounded medicines in 2023, and the blend is off-limits for tested athletes under WADA's S0 and S2 categories.

KLOW in Canada

Quick facts

KLOW — for sale in Canada

What is KLOW?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

KLOW FAQ

Research references